ArticleJournal of extracellular vesicles2020
Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p.
Article in Journal of extracellular vesicles, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 2 syntheses or guidelines pooled it, 238 citations in OpenAlex.
- Application of Extracellular Vesicles in Allergic Rhinitis: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Mesenchymal stromal cell extracellular vesicles as therapy for acute and chronic respiratory diseases: A meta-analysis.Journal of extracellular vesicles · 2021Pooled it
- Elevated miR-103b in exosomes derived from brain-metastatic triple-negative breast cancer cells remodels the brain pre-metastatic niche (PMN).Cancer biology & therapy · 2026Article
- Article
- Milk-derived extracellular vesicles loaded with miR-146a-5p as a novel therapeutic strategy for allergic airway inflammation.Molecular therapy. Nucleic acids · 2026Article
- Extracellular-Vesicle-Associated Nucleic Acids in the Diagnosis and Treatment of Respiratory Diseases: A Narrative Review.Pharmaceutics · 2026Review
- Label-Free Clustering Analysis Platform Drives Cascaded Workflow for Scalable Production of Therapeutic Extracellular Vesicles.Journal of extracellular vesicles · 2026Article
- A pH-responsive miR-146a-loaded Gel/MSN nanocarrier enhances anti-inflammatory efficacy in allergic rhinitis through pyroptosis suppression.Journal of translational medicine · 2026Article
- Extracellular Vesicles in Allergy: From Cellular Communication to Clinical Implications.Clinical reviews in allergy & immunology · 2026Review
- MSC-small extracellular vesicles alleviated Th2-airway inflammation by regulating the metabolism of DCs in mice.Stem cells translational medicine · 2026Article
- The Immunomodulatory Role of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Asthma.International journal of nanomedicine · 2026Review
- Mesenchymal Stem Cell-Derived Extracellular Vesicles Modulate the Course of Peritoneal Inflammation Through Metabolic and Epigenetic Regulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanoparticle-Based Targeted Drug Delivery Systems for Allergic Rhinitis: A Comprehensive Review.International journal of nanomedicine · 2026Review
- Mechanisms of Mesenchymal Stem Cell-Derived Exosomes in Dry Eye Disease: From Inflammation Pathways to Therapeutic Prospects.Stem cells international · 2026Review
- Mesenchymal stem cell-derived exosomes: a new hope for improving asthma airway remodeling.Annals of medicine · 2025Review
- Gingival mesenchymal stem cell-derived exosomal miR-23a-3p targets IL-6R to attenuate autoimmune insulitis: a cell-free therapeutic strategy for type 1 diabetes.Stem cell research & therapy · 2025Article
- Pathological noise exposure results in elevated levels of extracellular vesicles enriched with Hsp70 in the plasma.Journal of molecular medicine (Berlin, Germany) · 2025Article
- miRNA-146-a, miRNA-21, miRNA-143, miRNA-29-b and miRNA-223 as Potential Biomarkers for Atopic Dermatitis.Clinics and practice · 2025Article
- Mesenchymal stem cells for lung diseases: focus on immunomodulatory action.Cell death discovery · 2025Review
- A scalable platform for EPSC-Induced MSC extracellular vesicles with therapeutic potential.Stem cell research & therapy · 2025Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group 2 innate lymphoid cells (ILC2s) are recently reported to play a more critical role in allergic diseases. We previously identified that mesenchymal stromal cells (MSCs) elicited therapeutic effects on allergic airway inflammation. Small extracellular vesicles (sEV) derived from MSCs possess striking advantages including low immunogenicity and high biosafety, and is extremely promising cell-free therapeutic agents. However, the effects of MSC-sEV on ILC2s are still unclear. Additionally, scalable isolation protocols are required for the mass production of homogenous MSC-sEV especially in clinical application. We previously reported that induced pluripotent stem cells-derived MSCs were the ideal cellular source for the large preparation of MSC-sEV. Here we developed a standardized scalable protocol of anion-exchange chromatography for isolation of MSC-sEV, and investigated the effects of MSC-sEV on ILC2 function from patients with allergic rhinitis and in a mouse ILC2-dominant asthma model. The characterization of MSC-sEV was successfully demonstrated in terms of size, morphology and specific markers. Using flow cytometry and human Cytokine Antibody Array, MSC-sEV but not fibroblasts-sEV (Fb-sEV) were found to significantly inhibit the function of human ILC2s. Similarly, systemic administration of MSC-sEV but not Fb-sEV exhibited an inhibition of ILC2 levels, inflammatory cell infiltration and mucus production in the lung, a reduction in levels of T helper 2 cytokines, and alleviation of airway hyperresponsiveness in a mouse model of asthma. Using RNA sequencing, miR-146a-5p was selected as the candidate to mediate the above effects of MSC-sEV. We next revealed the uptake of ILC2s to MSC-sEV, and that transfer of miR-146a-5p in MSC-sEV to ILC2s in part contributed to the effects of MSC-sEV on ILC2s
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.